Search the GHTC website

Global health R&D delivers for New Jersey

US government investment in global health R&D has delivered

$114.8 million
to New Jersey research institutions
1,400+ new jobs
for New Jersey
Global health R&D at work in New Jersey

Rutgers New Jersey Medical School has helped develop a new rapid test for tuberculosis (TB). The test, Xpert® MTB/RIF Ultra, is a second-generation version of a test that revolutionized TB diagnosis. Like its predecessor, Ultra is fast, accurate, easy to use, and needs no extra equipment—making it particularly suitable for low-resource settings. But Ultra is better able to detect TB in children, people with HIV, and certain drug-resistant cases. Results from Ultra allow patients to start on treatment quickly, increasing treatment success rates and reducing the spread of the world’s top infectious killer.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: © 2013 Michael Tran/Interactive Research and Development, Courtesy of Photoshare